Distinguished in Peptic Ulcer

Nayoung D. Kim

Seoul, KR 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Peptic Ulcer
Seoul, KR 
OverviewLocationsClinical Research

Overview

Nayoung Kim practices in Seoul, Republic of Korea. Kim is rated as a Distinguished expert by MediFind in the treatment of Peptic Ulcer. Their top areas of expertise are Helicobacter Pylori Infection, Peptic Ulcer, Gastritis, Endoscopy, and Gastrectomy.

Their clinical research consists of co-authoring 386 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 40 articles in the study of Peptic Ulcer.

Locations

Seoul, Republic of Korea
Other Locations
Daejeon, Republic of Korea
Changwon, Republic of Korea
Yongin, Republic of Korea
Suwon, Republic of Korea
Chinju, Republic of Korea
Gyeongsan-si, Republic of Korea
Chuncheon, Republic of Korea
Gyeonggi-do, Republic of Korea
Cheonan, Republic of Korea
Songnam, Republic of Korea
Daegu, Republic of Korea
Gwangju, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A 12 Week, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of EDL on Dyspepsia
A 12 Week, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of EDL on Dyspepsia
Enrollment Status: Recruiting
Publish Date: November 29, 2024
Intervention Type: Dietary supplement, Other
Study Phase: Not Applicable
Effect of Helicobacter Pylori Eradication After Subtotal Gastrectomy on Survival Rate of Gastric Cancer Patients: Retrospective Study
Effect of Helicobacter Pylori Eradication After Subtotal Gastrectomy on Survival Rate of Gastric Cancer Patients: Retrospective Study
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Combination product
The Evaluation of OLGA and OLGIM Stage Systems for Prediction of Gastric Cancer Risk and Interaction With Other Risk Factors According to Lauren's Classification
The Evaluation of OLGA and OLGIM Stage Systems for Prediction of Gastric Cancer Risk and Interaction With Other Risk Factors According to Lauren's Classification
Enrollment Status: Completed
Publish Date: April 13, 2023
A Prospective, Single-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare the 14-day Bismuth Quadruple Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter as a Rescue 2nd Therapy.
A Prospective, Single-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare the 14-day Bismuth Quadruple Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter as a Rescue 2nd Therapy.
Enrollment Status: Terminated
Publish Date: April 13, 2023
Intervention Type: Drug, Procedure
Study Phase: Not Applicable
Long-term Follow-up of Interleukin-1B and H+,K+-ATPase mRNA Expression After Helicobacter Pylori Eradication
Long-term Follow-up of Interleukin-1B and H+,K+-ATPase mRNA Expression After Helicobacter Pylori Eradication
Enrollment Status: Completed
Publish Date: April 13, 2023
Expression of Neurotrophic Factors, Tight Junction Proteins, and Cytokines According to the Irritable Bowel Syndrome Subtype and Sex
Expression of Neurotrophic Factors, Tight Junction Proteins, and Cytokines According to the Irritable Bowel Syndrome Subtype and Sex
Enrollment Status: Completed
Publish Date: March 24, 2020
Intervention Type: Procedure
Study Phase: Not Applicable
A Prospective, Multi-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare 10-day Sequential Therapy and 14-day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea
A Prospective, Multi-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare 10-day Sequential Therapy and 14-day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea
Enrollment Status: Completed
Publish Date: May 13, 2019
Intervention Type: Drug
Study Phase: Not Applicable
View 6 Less Clinical Trials

386 Total Publications

Functional characterization of a novel plant growth-promoting rhizobacterium enhancing root growth and salt stress tolerance.
Functional characterization of a novel plant growth-promoting rhizobacterium enhancing root growth and salt stress tolerance.
Journal: Scientific reports
Published: June 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kim's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 75 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile